Mortality study of 18 000 patients treated with omeprazole

Area of Science:

• Gastroenterology
• Pharmacology
• Public Health

Background:

• The long-term safety of potent gastric acid suppressive therapies remains under investigation.
• Omeprazole is a widely prescribed proton pump inhibitor for acid-related gastrointestinal disorders.

Purpose of the Study:

• To evaluate the long-term safety and mortality risks associated with omeprazole use.
• To determine if omeprazole treatment increases mortality, particularly from esophageal cancer.

Main Methods:

• A retrospective review of general practice records for 17,936 patients prescribed omeprazole between 1993-1995.
• Mortality data over four years were obtained from UK National Health Service Central Registers and compared to general population rates.
• Specific causes of death, including cancers, were analyzed in relation to pre-existing conditions.

Main Results:

• All-cause mortality was elevated in the first year of omeprazole use but normalized by the fourth year.
• Increased mortality from neoplasms, circulatory, and respiratory diseases in the first year subsided by the fourth year.
• A persistent increase in digestive disease mortality was observed, with a significant association between esophageal cancer deaths and pre-existing severe esophageal conditions.

Conclusions:

• Elevated mortality rates associated with omeprazole are attributed to pre-existing illnesses, especially severe esophageal disease.
• No increased risk of esophageal adenocarcinoma was found in patients without pre-existing esophageal mucosal damage.
• The study suggests omeprazole's safety profile is acceptable when considering underlying patient conditions.